Avidity Biosciences, Inc.RNAEarnings & Financial Report
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
Revenue
$3.8M
Gross Profit
N/A
Operating Profit
$-171.1M
Net Profit
$-157.3M
Gross Margin
N/A
Operating Margin
-4448.7%
Net Margin
-4089.3%
YoY Growth
88.1%
EPS
$-1.21
Avidity Biosciences, Inc. Q2 FY2025 Financial Summary
Avidity Biosciences, Inc. reported revenue of $3.8M (up 88.1% YoY) for Q2 FY2025, with a net profit of $-157.3M (down 122.2% YoY) (-4089.3% margin).
Key Financial Metrics
| Total Revenue | $3.8M |
|---|---|
| Net Profit | $-157.3M |
| Gross Margin | N/A |
| Operating Margin | -4448.7% |
| Report Period | Q2 FY2025 |
Avidity Biosciences, Inc. Annual Revenue by Year
Avidity Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $10.9M |
| 2023 | $9.6M |
| 2022 | $9.2M |
Avidity Biosciences, Inc. Quarterly Revenue & Net Profit History
Avidity Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $12.5M | +434.0% | $-174.4M | -1398.3% |
| Q2 FY2025 | $3.8M | +88.1% | $-157.3M | -4089.3% |
| Q1 FY2025 | $1.6M | -55.6% | $-115.8M | -7360.0% |
| Q4 FY2024 | $3.0M | +35.6% | $-102.3M | -3439.5% |
| Q3 FY2024 | $2.3M | -17.1% | $-80.4M | -3441.7% |
| Q2 FY2024 | $2.0M | -11.7% | $-70.8M | -3461.8% |
| Q1 FY2024 | $3.5M | +58.7% | $-68.9M | -1943.4% |
| Q4 FY2023 | $2.2M | -20.8% | $-60.4M | -2756.2% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.5M | $2.0M | $2.3M | $3.0M | $1.6M | $3.8M | $12.5M |
| YoY Growth | -20.8% | 58.7% | -11.7% | -17.1% | 35.6% | -55.6% | 88.1% | 434.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $628.6M | $951.5M | $1.35B | $1.64B | $1.56B | $1.46B | $1.37B | $2.13B |
| Liabilities | $127.8M | $120.6M | $126.4M | $137.4M | $138.9M | $130.4M | $176.3M | $247.9M |
| Equity | $500.8M | $830.9M | $1.22B | $1.50B | $1.42B | $1.33B | $1.19B | $1.89B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $16.5M | $-70.4M | $-65.0M | $-65.6M | $-99.9M | $-124.8M | $-199.7M | $-156.2M |